

Sister Study First DCIS or Invasive Breast Cancer Events ¹ Stratified by Race/Ethnicity ²: Data Release 11.0 ³

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,961)	%	N (total = 384)	%	N (total = 282)	%
Breast Cancer Subtype for 1st DCIS or Invasive Diagnosis						
Invasive ⁴	3,151	79.6	284	74.0	234	83.0
Ductal only (no lobular component) ⁵	2,185	55.2	176	45.8	164	58.2
Lobular only (no ductal component) ⁵	284	7.2	13	3.4	14	5.0
Ductal and lobular ^{5,6}	216	5.5	9	2.3	14	5.0
Inflammatory	7	0.2	3	0.8	0	0.0
Paget's	11	0.3	2	0.5	0	0.0
Phyllodes ⁷	5	0.1	0	0.0	0	0.0
Other/unknown if ductal or lobular ⁸	443	11.2	81	21.1	42	14.9
<i>In situ</i>	805	20.3	100	26.0	47	16.7
Ductal only (no lobular component) ⁹	782	19.7	96	25.0	47	16.7
Ductal and lobular ^{6,9}	14	0.4	1	0.3	0	0.0
Paget's	6	0.2	0	0.0	0	0.0
Other/unknown if ductal or lobular ¹⁰	3	0.1	3	0.8	0	0.0
Invasiveness unknown ¹¹	5	0.1	0	0.0	1	0.4
Stage at 1st DCIS or Invasive Diagnosis ¹²						
0	744	21.3	82	27.6	45	18.8
I	1,868	53.4	122	41.1	124	51.7
II	692	19.8	72	24.2	48	20.0
III	170	4.9	19	6.4	21	8.8
IV	22	0.6	2	0.7	2	0.8
<i>Unknown, missing, cannot stage</i>	465		87		42	
Estrogen Receptor (ER) Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	2,934	85.9	205	74.5	189	84.0
Negative	478	14.0	68	24.7	36	16.0
Borderline	3	0.1	2	0.7	0	0.0
<i>Unknown, missing, not performed</i>	546		109		57	
Progesterone Receptor (PR) Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	2,466	74.2	159	59.6	153	70.8
Negative	851	25.6	107	40.1	63	29.2
Borderline	7	0.2	1	0.4	0	0.0
<i>Unknown, missing, not performed</i>	637		117		66	

Characteristic	Non-Hispanic White		Black (includes Hispanic Black)		Non-Black Hispanic/Other	
	N (total = 3,961)	%	N (total = 384)	%	N (total = 282)	%
HER2 Amplification Status: 1st DCIS or Invasive Breast Cancer ¹²						
Positive	339	11.8	33	15.1	35	17.6
Negative	2,482	86.7	184	84.4	162	81.4
Borderline	41	1.4	1	0.5	2	1.0
<i>Unknown, missing, not performed</i>	1,099		166		83	
Combined ER, PR, HER2 Status: 1st DCIS or Invasive Breast Cancer ¹²						
Triple negative (ER-, PR-, and HER2-)	259	7.8	45	16.9	18	8.3
Not triple negative	3,058	92.2	221	83.1	200	91.7
<i>Unknown, missing, not performed</i>	644		118		64	
Diagnosis Confirmation ¹³						
Medical	3,327	84.0	261	68.0	222	78.7
NDI Plus or death certificate	40	1.0	16	4.2	3	1.1
None	594	15.0	107	27.9	57	20.2
Age (in years) at 1st DCIS or Invasive Breast Cancer ¹⁴						
Under 50	325	8.2	50	13.0	35	12.4
50-64	1,657	41.8	177	46.1	159	56.4
65 and older	1,979	50.0	157	40.9	88	31.2
Menopausal Status at 1st DCIS or Invasive Breast Cancer						
Pre-menopausal	543	13.7	62	16.2	56	19.9
Post-menopausal	3,418	86.3	321	83.8	226	80.1
<i>Unknown</i>	0		1		0	

Abbreviations: DCIS=Ductal carcinoma *in situ*; BrCa= Breast cancer; MR = Medical report (medical record and/or pathology report)

¹ Breast cancer events (1st DCIS or invasive) are defined by the following ICD10 codes: D05.1 (ductal carcinoma *in situ*), C50 (all invasive breast cancer), and ductal D48.6 (neoplasm of uncertain behavior of breast)

² Excludes n=1 where race/ethnicity is missing

³ Data release 11.0 includes events from follow-up phases that closed **on or before 9/30/2021**, excluding any data from participants who have withdrawn their data from the study (n=5). To be considered a breast cancer event, breast must be the primary site, and the cancer diagnosis must have occurred after the participant's baseline date. Consequently, Data Release 11.0 breast cancer events for 1st DCIS or invasive diagnosis exclude a) through c) below:

- a) Breast cancers diagnosed prior to participant's baseline date;
- b) Breast cancers diagnosed with unknown timing relative to baseline;
- c) Unknown primary cancer diagnoses where breast was unlikely to be the primary site, but the possibility could not be ruled out

⁴ Includes 'presumed invasive' (i.e., a carcinoma *in situ* with positive nodes)

⁵ Invasive Ductal only, Invasive Lobular only, and Invasive Ductal and Lobular exclude inflammatory breast cancer and Paget's

- ⁶ Includes BrCa events with a) tumors with mixed ductal and lobular characteristics and/or b) multiple tumors of different histology (e.g. a ductal only tumor and a lobular only tumor)
- ⁷ Phyllodes is neither ductal nor lobular; it is a sarcoma
- ⁸ Includes: a) Invasive but unknown if ductal or lobular, these are typically self-report without MR confirmation; b) Invasive type “neither ductal nor lobular, not otherwise specified”, these are typically self-report without MR confirmation; and c) Per MR, presumed invasive - *in situ* tumor, positive nodes
- ⁹ *In situ* Ductal only and *in situ* Ductal and Lobular exclude *in situ* Paget’s
- ¹⁰ Excludes all with known lobular-only origin but includes *in situ* diagnoses where unknown if ductal or lobular, these are typically self-report without MR confirmation
- ¹¹ Invasiveness unknown includes: a) Unknown if DCIS or invasive ductal and b) Per MR, unable to determine if DCIS or atypical ductal hyperplasia
- ¹² Priority for stage and ER/PR/HER2 status when diagnosis is reported by multiple sources: Medical record>Breast Cancer Follow-Up Form
- ¹³ Medical confirmation of reported breast cancer is generally from medical records but may only include pathology report; National Death Index (NDI) Plus or death certificate confirmation is specific to cases that do not have medical confirmation
- ¹⁴ For those missing age at diagnosis, age was imputed as the midpoint of the range of plausible ages at diagnosis